Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 12, 2011Journal of Clinical OncologyOpen Access

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMichael LübbertUniversity of FreiburgSSStefan SuciuUniversité Paris-SudLBLiliana BailaRadboud University Nijmegen

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lübbert et al. (2011) studied this question.

synapsesocial.com/papers/69ecef1dd55980bedc8fe5b4https://doi.org/10.1200/jco.2010.30.9245
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia1992 · 80 citations
  2. 2International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes1997 · 4,484 citations
  3. 3Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial2009 · 317 citations